

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

INSIDE INFORMATION RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) APPROVED AS HETEROLOGOUS BOOSTER VACCINE IN CHINA

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that, as announced by the Joint Prevention and Control Mechanism of the State Council in Response to the Novel Coronavirus Pneumonia, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia) (the “**Convidecia**”) has been approved as a heterologous booster COVID-19 vaccine in China. Target population of adults 18 years and older who have completed the primary vaccination of inactivated COVID-19 vaccines produced by Beijing Institute of Biological Products Co., Ltd. (北京生物製品研究所有限責任公司), Sinovac Life Sciences Co., Ltd. (北京科興中維生物技術有限公司) or Wuhan Institute of Biological Products Co., Ltd. (武漢生物製品研究所有限責任公司) may choose Convidecia as a one-dose heterologous booster vaccine with a minimum interval of six months after the primary vaccination. Heterologous boosting with Convidecia can significantly increase the neutralizing antibody level of vaccinated population with proven safety.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, February 20, 2022

As of the date of this announcement, the board of directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.